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E-mail address: kbirukov@medicine.bsd.uchicago.eBarrier-protective agonists induce association of focal adhesions (FA) and adherens junctions (AJ) in
endothelial cells. Here we identiﬁed speciﬁc domains of FA protein paxillin interacting with AJ pro-
tein and examined regulation of paxillin domain interactions with b-catenin by Rac GTPase.
Co-expression of paxillin LD-1,2; LD-3,4; LIM-1,2; and LIM-3,4 domains with b-catenin showed
exclusive interaction of LIM-1,2 and LIM-3,4 with b-catenin, which was enhanced by agonist-
induced Rac activation or expression of activated Rac mutant. These results demonstrate a novel
function of paxillin LIM domains in targeting b-catenin in a Rac-dependent manner, which may play
a role in Rac-dependent control of FA-AJ interactions and monolayer integrity.
Structured summary of protein interactions:
Paxillin binds to Beta-catenin by pull down (View interaction)
Beta-catenin physically interacts with Paxillin by anti bait coimmunoprecipitation (View interaction)
Paxillin physically interacts with GIT2 by pull down (View interaction)
Paxillin physically interacts with Beta-catenin by pull down (View Interaction: 1, 2)
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Focal adhesions (FA) and adherens junctions (AJ) are critical
structural elements in the maintenance of monolayer integrity
[1]. In addition, speciﬁc proteins from FA, AJ and tight junction
adhesive complexes may interact with each other [2–4]. Paxillin
is a multi-domain adapter FA protein that functions as a molecular
scaffold for protein recruitment to FA and thereby facilitates
protein networking and efﬁcient signal transmission [5,6]. The
N-terminal domain of paxillin contains several copies of the
so called LD motif, which function as binding sites for other FA-
associated proteins. The C-terminal half of paxillin contains four
LIM domains, also involved in protein–protein interactions. The
LIM-3 domain targets paxillin to focal adhesions, while the LIM-2
domain plays a minor role in this process (see [7] for review).
These LIM domains engage binding partners to direct and/or tether
paxillin to focal adhesions, but the complete list of LIM-domain
binding partners remains to be identiﬁed. Through the multiple
SH2- and SH3-binding domains, LIM, and LD motifs, paxillin
interacts with the signaling proteins focal adhesion kinase (FAK),chemical Societies. Published by E
er, Section of Pulmonary and
of Chicago, 5841 S. Maryland
3 834 2683.
du (K.G. Birukov).p60Src-kinase, Crk, Csk, Pyk2, ILK, and the structural focal adhe-
sion-associated proteins vinculin, actopaxin, and tubulin [5,8]. In
addition to the classical paxillin binding partners, new candidate
molecules have been recently reported, and the sites of paxillin
interaction with these proteins remain to be deﬁned.
We have previously reported that in pulmonary endothelium
oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine
(OxPAPC) induced paxillin peripheral translocation and co-locali-
zation with the AJ protein b-catenin [9], which was linked to
endothelial barrier enhancement. This study used a molecular
dissection approach to identify paxillin domains involved in inter-
action with b-catenin and examined their potential role in
OxPAPC-induced endothelial signaling.2. Materials and methods
An expanded Materials and methods section is available in the
online data supplement.2.1. Reagents and cell culture
Unless speciﬁed, biochemical reagents were obtained from
Sigma (St. Louis, MO). Paxillin, b-catenin, Rac1, and GIT2 antibodies
were purchased from BD Transduction Laboratories (San Diego,lsevier B.V. All rights reserved.
O. Dubrovskyi et al. / FEBS Letters 586 (2012) 2294–2299 2295CA); GST, p-coﬁlin, and p-Vav2 antibodies were from Santa Cruz
Biotechnology (Santa Cruz, CA). Recombinant EGF was from R&D
Systems (Minneapolis, MN). HEK293T cells (ATTC, Washington,
DC) were cultured in Dulbecco’s modiﬁed Eagle’s medium supple-
mented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA).
Human pulmonary artery endothelial cells (HPAEC) were obtained
from Lonza (Allendale, NJ), cultured in cell growth medium (EGM-
2, Lonza) containing 10% fetal bovine serum (FBS) and used at pas-
sages 5–8.
2.2. Plasmid construction
Human paxillin from HPAEC was cloned, and paxillin truncated
mutants encompassing LD-1,2; LD-3,4; LIM-1,2; and LIM-3,4 do-
mains were generated, as described in the Online Supplementary
data.
2.3. GST pull-down assays and immunoprecipitation
Control or EGF-stimulated HEK293T cells transfected with GST-
tagged full length or paxillin domians, or 6-His-tagged b-catenin
were subjected to pulldown assays, as described in the Online
Supplementary data. Co-immunoprecipitation of b-catenin–paxil-
lin assays have been described previously [9].
2.4. Rac activation assay
Activation of Rac1 GTPase was monitored by accumulation of a
GTP-bound Rac1 pool in stimulated cells using a Rac in vitro
pulldown assay with PAK-PBD beads, as described elsewhere
[10].
2.5. Measurements of transendothelial electrical resistance
Across conﬂuent endothelial cell monolayer were performed
using the electrical cell-substrate impedance sensing system
ECIS-1600 (Applied Biophysics, Troy, NY) as described elsewhere
[10].
2.6. Statistical analysis
Results are expressed as mean ± SD of three to six independent
experiments. Experimental samples were compared to controls by
unpaired Student’s t-test. For multiple-group comparisons, a one-
way analysis of variance (ANOVA) and Tukey’s post hoc multiple-
comparison test were used. P < 0.05 was considered statistically
signiﬁcant.Fig. 1. Expression of paxillin and its truncated domains in HEK293T. Schem3. Results
3.1. Paxillin b-catenin interaction is mediated by LIM domains of
paxillin
In order to identify paxillin regions interacting with b-catenin,
we cloned human paxillin from human pulmonary endothelial
cells and generated paxillin truncated mutants encompassing LD-
1,2; LD-3,4; LIM-1,2; and LIM-3,4 domains (Supplementary data,
Fig. S1). Schematic paxillin domain structure (see [7] for review)
and diagrams of GST-fused paxillin constructs used in this study
are presented in Fig. 1.
Paxillin–b-catenin interactions were detected in HEK293T cells
ectopically expressing paxillin and b-catenin in co-immunoprecip-
itation assays under non-denaturing conditions (Fig. 2A). The con-
tent of paxillin in b-catenin immunoprecipitates was determined
using GST antibody. Non-transfected cells served as a negative
control.
In the next experiments, GST-tagged full length paxillin or its
domains were overexpressed in HEK293T (Fig. 2B) followed
by immobilization on GSH beads. Pulldown of b-catenin was
performed by loading of HEK293T lysates with overexpressed
6-His-tagged b-catenin onto GSH-paxillin beads. We observed
strong interactions of b-catenin with full length paxillin, LIM-1,2,
and LIM-3,4 domains, while no b-catenin interaction was detected
with paxillin mutants containing LD-1,2 and LD-3,4 domains
(Fig. 2C). To ensure that paxillin domains in these pulldown exper-
iments maintained their protein binding capacities, we tested the
well-characterized interaction between paxillin and its FA partner,
short form GIT2, using a panel of paxillin deletion mutants. In
agreement with previous studies showing interaction of GIT2 with
the LD-4 domain of paxillin [11], the paxillin mutant containing
LD-3,4 domains interacted with sGIT2, whereas no interaction with
other domains was found (Fig. 2D).
In agreement with the experiments in HEK293T cells, GST pull-
down assays revealed a strong interaction of endogenous b-catenin
from human pulmonary EC lysates with bacterially expressed re-
combinant full length paxillin and its LIM-1,2 and LIM-3,4 do-
mains. Of note, no interaction between b-catenin and paxillin LD
domains was detected (Fig. 2E).
3.2. Bacterially expressed puriﬁed paxillin and b-catenin interact in
pulldown assay
Because paxillin may interact with any of the large number of
proteins within the focal adhesion multi-protein complex in mam-
malian cells, it is conceivable that the interaction with b-cateninatic presentation paxillin and b-catenin constructs used in this study.
Fig. 2. Determination of paxillin domains involved in interaction with b-catenin.
(A) HEK293T cells were transected with GST-tagged paxillin or its domains and 6-
His-tagged b-catenin constructs. After 48 h of transfection, immunoprecipitation of
b-catenin was performed under non-denaturing conditions using b-catenin anti-
body. The content of recombinant paxillin in the immunoprecipitates was deter-
mined using GST antibodies. (B–D) HEK293T cells were co-transected with paxillin
and b-catenin constructs. Control transfections were performed with empty
vectors. Expression of GST-tagged full length paxillin and its truncated domains
was determined by western blot analysis with GST antibody. Expression of 6-His-
tagged b-catenin was conﬁrmed by western blot analysis with His antibody or b-
catenin antibody (B). GST-tagged full length paxillin and truncated domains were
immobilized on GSH-beads. Total cell lysates from HEK293T overexpressing 6-His-
tagged b-catenin were added to the beads, and bound proteins were analyzed by
western blot. Content of b-catenin (C) and short form of GIT2 (D) bound to GSH-
beads was detected with corresponding antibodies. E: HPAEC lysates were loaded
onto GSH-beads conjugated with full length GST-paxillin or corresponding paxillin
domains expressed in bacteria. A pulldown assay was performed, and the amount of
b-catenin bound to GST-tagged bacterial proteins was determined by western blot
with b-catenin antibody. Equal loading of recombinant paxillin beads used for
pulldown assays with HPAEC lysates was determined by western blot with GST
antibody.
Fig. 3. Interaction between paxillin and b-catenin expressed in E. coli. (A) Full
length paxillin and b-catenin were expressed in E. coli (strain BL21-AI). Fusion
proteins were puriﬁed using GSH-Sepharose and Ni-column, respectively, and
analyzed by SDS–PAGE followed by Coomassie staining. (B) 6-His-tagged b-catenin
and full length GST-tagged paxillin expressed in the bacterial system were tested in
a GST-pulldown assay. GST conjugated to the beads alone served as negative
control. After washing steps, beads were treated with SDS sample buffer, and bound
paxillin and b-catenin were determined by western blot with corresponding
antibody.
Fig. 4. Interaction between paxillin and b-catenin is Rac1 dependent. A: HEK293T
were stimulated with EGF (500 ng/ml) for the indicated periods of time. Rac
activation was evaluated by Rac-GTP pulldown assay. Upper panel depicts the
levels of activated GTP-bound Rac. The total Rac content in whole cell lysates is
shown on the lower panel. B: HEK293T were transfected with full length GST-
paxillin or 6-His-b-catenin followed by stimulation with vehicle or EGF (500 ng/ml,
15 min). Cells lysates were combined, and GST pulldown was performed as
described in Materials and methods. Content of paxillin-bound b-catenin was
determined by western blot with b-catenin antibody. Equal protein loading was
conﬁrmed by detection of the housekeeping protein b-tubulin in whole cell lysates.
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experiments performed in the HEK293T cell system may be indi-
rect. To rule out this possibility, we separately expressed 6-His-
tagged full-length b-catenin and GST-fused full length paxillin
(Fig. 3A) in a bacterial system (BL21-AI Escherichia coli), and per-
formed a GST pulldown assay of puriﬁed proteins. In agreement
with experiments performed in transfected HEK293T cells, paxillin
and b-catenin expressed in E. coli efﬁciently interacted with each
other, thus supporting a direct mechanism of paxillin-b-catenin
interaction (Fig. 3B).
3.3. Rac regulation of b-catenin interactions with paxillin domains and
control of Rac signaling by LIM domains
The following studies examined whether Rac GTPase activation
stimulates interactions between ectopically expressed b-catenin
and paxillin. Our test experiments showed that epithelial growth
factor (EGF) causes pronounced Rac activation in HEK293T
(Fig. 4A). Cells were transfected separately with full length paxillin
or B-catenin constructs and treated with EGF before lysis. Cell
ysates from paxillin or b-catenin transfected cells were combined,
and GST-paxillin was pulled down with GSH-beads. EGF stimula-
tion of either full length paxillin or b-catenin expressing cellsFig. 5. Interaction between paxillin and b-catenin is Rac dependent. (A) HEK293T we
dominant negative (Rac1-N17) or constitutively active (Rac1-V12) Rac mutants, and full l
vehicle or EGF (500 ng/ml, 15 min) and lysed. Pulldown assays on GSH beads were perfor
paxillin or its domains was determined by western blot analysis with corresponding anti
in whole cell lysates using GST antibody (lower panel). (B) Quantiﬁcation of pulldown exp
determined by quantitative densitometry of western blot membranes and normalized
densitometry are expressed as b-catenin/GST ratio and shown as mean ± SD, ⁄P < 0.05 vincreased paxillin-b-catenin interaction, as compared to non-
stimulated lysates. However, maximal binding was observed when
both paxillin-expressing and b-catenin-expressing cells were stim-
ulated with EGF simultaneously (Fig. 4B).
Next, we investigated the role of Rac in the regulation of inter-
actions between paxillin domains and b-catenin. HEK293T cells
were co-transfected with full length paxillin or its domains and
dominant negative or constitutively active Rac mutants (Rac1-
N17 and Rac1-V12, respectively). GST proteins were immobilized
on GSH beads and used for GST pulldown assays with cell lysates
overexpressing b-catenin. In consistence with results obtained in
non-stimulated cells, neither Rac activation using EGF treatment,
nor expression of activated Rac caused interactions between
b-catenin and paxillin LD domains (Fig. 5A). In contrast, agonist-
induced Rac activation or expression of Rac1-V12 mutant dramat-
ically increased interactions between b-catenin and full length
paxillin or its LIM domains. In contrast, molecular inhibition of
Rac activity by overexpression of dominant negative Rac signiﬁ-
cantly suppressed EGF-induced b-catenin interactions with full
length paxillin and its LIM domains. These experiments demon-
strate the Rac-dependent mechanism of increased paxillin-b-cate-
nin interactions. Quantitative analysis of pulldown results is
presented in Fig. 5B.re co-transfected with full length GST-tagged paxillin or its domains, HA-tagged
ength His-tagged b-catenin. After 48 h of transfection, the cells were stimulated with
med as described in Materials and methods. The content of b-catenin bound to GST-
body (upper panel). Expression levels of GST-tagged paxillin mutants were detected
eriments. Amount of b-catenin bound to GSH beads with paxillin or its domains was
to the amount of immobilized paxillin and its domains on the beads. Results of
s. non-stimulated control; n = 4.
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cells
The functional signiﬁcance of paxillin LIM-3,4 domains was fur-
ther tested in human pulmonary artery endothelial cells (HPAEC),
which were transiently transfected with full length GFP-tagged
paxillin or a truncated paxillin mutant containing LIM-3,4 do-
mains. OxPAPC-induced elevation of transendothelial electrical
resistance (TER) reﬂecting HPAEC barrier enhancement was moni-
tored over time. Similarly to non-transfected cells [12, #911],
OxPAPC stimulation of cells expressing full length paxillin caused
a rapid and sustained TER increase. Ectopic expression of LIM-3,4
did not signiﬁcantly affect the acute phase of OxPAPC-induced bar-
rier response, but suppressed the prolonged phase of barrier
enhancement (Fig. 6A).
We next evaluated the effects of LIM-3,4 expression on OxPAPC-
induced signaling. Similarly to non-transfected cells [13], OxPAPCFig. 6. Effects of paxillin LIM-3,4 domain expression on OxPAPC-induced endothe-
lial barrier enhancement and Rac pathway activation in pulmonary endothelial
cells. HPAEC were transfected with full length GST-tagged paxillin or its LIM-3,4
domain. After 48 h of transfection, the cells were stimulated with vehicle or OxPAPC
(15 mg/ml). (A) Changes in transendothelial electrical resistance were monitored
over time. (B) Site-speciﬁc phosphorylation of PAK and cortactin was detected by
Western blot. Equal protein loading was conﬁrmed by determination of b-tubulin
and paxillin content in total cell lysates. Expression level of GFP-tagged full length
paxillin was detected in whole cell lysates using paxillin monoclonal antibody
antibody (clone 349), GST-LIM-3,4 was detected using GST antibody.treatment of HPAEC transfected with full length paxillin induced
sustained phosphorylation/activation of the Rac downstream tar-
get, PAK1 and also caused phosphorylation of the regulator of actin
remodeling, cortactin (Fig. 6A). Ectopic expression of the paxillin
LIM-3,4 domain did not affect OxPAPC-induced PAK1 and cortactin
phosphorylation at early time points (5 min), but caused signiﬁ-
cant reduction at the later (30 min) time points. Collectively, these
results suggest negative effects of paxillin LIM-3,4 domain expres-
sion on OxPAPC-induced signaling and EC barrier enhancement.
4. Discussion
This study demonstrates for the ﬁrst time a key role of LIM do-
mains in paxillin interaction with b-catenin. Pulldown assays with
bacterially expressed proteins further conﬁrmed the direct nature
of these interactions. We found that both paxillin fragments, each
containing two LIM domains (LIM-1,2 and LIM-3,4, respectively),
interacted with b-catenin. Because LIM domains exhibit a high de-
greeofhomology,wespeculate thatb-cateninmaypotentially inter-
act with any LIM domain depending on its availability in particular
conditions. However, other potential binding regions, such as short
linker regions connecting LIM domains cannot be completely ex-
cluded. It was noted that paxillin binding to other protein partners
(actopaxin, FAK) may also involve more than one domain [14,15].
Several complementary approaches used in this study, includ-
ing EGF-induced activation of endogenous Rac, ectopic expression
of constitutively active Rac mutant, and Rac inhibition by expres-
sion of dominant negative Rac mutant strongly suggest direct
involvement of Rac in the regulation of paxillin–b-catenin interac-
tions via paxillin LIM domains. We also do not exclude Rac-
induced activation of tyrosine phosphorylation as an additional
step to enhancement of b-catenin interactions with paxillin. Pub-
lished studies noted that paxillin phosphorylation at serine and
threonine residues may inﬂuence paxillin conformation and there-
by allosterically affect its ability to interact with speciﬁc binding
partners [7].
Our previous report described a positive feedback mechanism
of OxPAPC-induced Rac activation via the PAK1–paxillin–bPIX pro-
tein complex [13]. This mechanism contributes to the maintenance
of local Rac activity at the cell periphery which promotes enhance-
ment of cortical cytoskeleton and cell-cell junctions leading to
strengthening of the endothelial barrier. The expression of paxillin
LIM-3,4 domains in this study attenuated OxPAPC-induced Rac
signaling and abrogated the sustained phase of EC barrier
enhancement.
We speculate that in non-transfected cells, OxPAPC-induced
Rac activation promotes interaction of b-catenin with paxillin
via LIM domains and therefore targets paxillin to adherence junc-
tions. In turn, over-expression of LIM domains uncouples Rac-
induced association of b-catenin with endogenous full-length
paxillin, as well as abrogates positive feedback regulation of Rac
activity, which involves paxillin phosphorylation at Serine-273
[13,16]. Altogether, these events may lead to the formation of less
stable cell-cell interactions and compromised EC barrier enhance-
ment. We also do not exclude other LD-dependent signaling
mechanisms which can affect OxPAPC-mediated barrier enhance-
ment. Finally, overexpression of LIM domains may also displace
endogenous paxillin from the focal adhesions and further com-
promise interactions between adherens junctions and focal adhe-
sions upon OxPAPC stimulation. These potentially important
mechanisms await further investigation.
5. Conclusions
This study identiﬁed LIM domains as domains mediating
paxillin interaction with b-catenin. A direct mechanism of b-
O. Dubrovskyi et al. / FEBS Letters 586 (2012) 2294–2299 2299catenin–paxillin interactions has been conﬁrmed in experiments
with recombinant proteins expressed in E. coli. However, Rac-
dependent enhancement of b-catenin–paxillin complex formation
has been observed, which suggests an allosteric mechanism of reg-
ulation, and which possibly involves other paxillin domains. These
results suggest that perturbations in paxillin LIM domain interac-
tions with other protein partners may affect cell signaling and
cytoskeletal dynamics, the key features of cell motility and endo-
thelial permeability. Future characterization of functional activities
of paxillin LIM domains may reveal novel mechanisms regulating
Rac signaling and endothelial permeability in physiological and
pathological settings.
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